Jann_1998_Pharmacotherapy_18_55

Reference

Title : Preclinical pharmacology of metrifonate - Jann_1998_Pharmacotherapy_18_55
Author(s) : Jann MW
Ref : Pharmacotherapy , 18 :55 , 1998
Abstract : Alzheimer's disease is a chronic neurodegenerative disorder that is characterized by memory impairment, cognitive dysfunction, behavioral disturbances, and deficits in activities of daily living. A consistent observation in these patients is that cholinergic neurons are affected and deteriorate over time, leading to decreased levels of acetylcholine (ACh). Acetylcholinesterase (AChE) inhibitors, which attempt to prevent the breakdown of ACh, may be classified as short acting, intermediate acting, and long acting based on AChE regeneration time. Metrifonate is converted by a nonenzymatic process to the long-acting cholinesterase inhibitor 2,2-dichlorovinyl dimethyl phosphate (DDVP). Acetylcholinesterase inhibition produced by metrifonate occurs rapidly, is dose dependent, can be detected by inhibition measured in red blood cells, and can be reversed by oxime administration. Metrifonate and DDVP improved performance in young rats; cognitive improvement in aged rats also was observed. Both agents were well tolerated and did not have significant effects on various preclinical pharmacologic safety tests.
ESTHER : Jann_1998_Pharmacotherapy_18_55
PubMedSearch : Jann_1998_Pharmacotherapy_18_55
PubMedID: 9543466

Related information

Citations formats

Jann MW (1998)
Preclinical pharmacology of metrifonate
Pharmacotherapy 18 :55

Jann MW (1998)
Pharmacotherapy 18 :55